Apple Tree’s Chapter 11 cases are moving toward a proposed restructuring backed by the fund’s previously disputing majority investors. The fund has requested approval of a plan support agreement and up to $24.79 million in new financing; objections are due November 16, 2026, and the proposed agreement targets a plan filing by December 7. Plan support motion Dkt. 1282 Financing motion Dkt. 1280

Apple Tree Life Sciences, Inc.’s Chapter 11 cases are proceeding toward a proposed fund restructuring under an agreement with its majority investors, Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP. On October 30, 2026, affiliate ATP Life Science Ventures, L.P. sought approval to enter into the plan support agreement Dkt. 1282, which contemplates a plan for the fund and participating portfolio companies, alongside a potential sale process for other participating companies. The proposed plan would generally pay allowed claims in full or leave them unimpaired and reinstate existing equity. Joining sale-track companies would be marketed with the fund as the proposed stalking-horse bidder.

The fund also requested approval of up to $24.79 million in new-money, delayed-draw financing from the Rigmora investors for case expenses, working capital and portfolio-company funding. The proposed loans would be available in monthly installments beginning December 10, 2026, subject to approval, conditions and the budget. The investors’ proposed exit financing remains subject to definitive documentation, with its size and terms still to be agreed. Objections to the financing motion Dkt. 1280 and plan support motion are due November 16, 2026. The agreement targets portfolio-company joinders by November 23, a plan and disclosure statement by December 7, confirmation by February 22, 2027, and effectiveness by March 22, 2027.

Apple Tree, the operating company of a biotechnology venture capital enterprise, filed for Chapter 11 on December 9, 2025, along with the fund and its general partner. The debtors attributed their liquidity crisis to the Rigmora investors’ failure to fund capital calls and difficulties obtaining replacement financing. According to the first-day declaration Dkt. 18, the Delaware Court of Chancery ordered the investors on December 5, 2025, to fund $96,960,925.88, but the money had not been received when the declaration was filed. The funding shortfall had disrupted portfolio-company research and operations.

A separate dispute over counsel is also before the court. The fund’s October 27 disqualification motion Dkt. 1270 alleges that its former bankruptcy counsel, Quinn Emanuel, took adverse positions while representing seven portfolio debtors and the general partner; it seeks the firm’s disqualification from those representations. A hearing is scheduled for November 10, 2026.

Apple Tree’s Chapter 11 cases are moving toward a proposed restructuring backed by the fund’s previously disputing majority investors. The fund has requested approval of a plan support agreement and up to $24.79 million in new financing; objections are due November 16, 2026, and the proposed agreement targets a plan filing by December 7. Plan support motion Dkt. 1282 Financing motion Dkt. 1280

Apple Tree Life Sciences, Inc.’s Chapter 11 cases are proceeding toward a proposed fund restructuring under an agreement with its majority investors, Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP. On October 30, 2026, affiliate ATP Life Science Ventures, L.P. sought approval to enter into the plan support agreement Dkt. 1282, which contemplates a plan for the fund and participating portfolio companies, alongside a potential sale process for other participating companies. The proposed plan would generally pay allowed claims in full or leave them unimpaired and reinstate existing equity. Joining sale-track companies would be marketed with the fund as the proposed stalking-horse bidder.

The fund also requested approval of up to $24.79 million in new-money, delayed-draw financing from the Rigmora investors for case expenses, working capital and portfolio-company funding. The proposed loans would be available in monthly installments beginning December 10, 2026, subject to approval, conditions and the budget. The investors’ proposed exit financing remains subject to definitive documentation, with its size and terms still to be agreed. Objections to the financing motion Dkt. 1280 and plan support motion are due November 16, 2026. The agreement targets portfolio-company joinders by November 23, a plan and disclosure statement by December 7, confirmation by February 22, 2027, and effectiveness by March 22, 2027.

Apple Tree, the operating company of a biotechnology venture capital enterprise, filed for Chapter 11 on December 9, 2025, along with the fund and its general partner. The debtors attributed their liquidity crisis to the Rigmora investors’ failure to fund capital calls and difficulties obtaining replacement financing. According to the first-day declaration Dkt. 18, the Delaware Court of Chancery ordered the investors on December 5, 2025, to fund $96,960,925.88, but the money had not been received when the declaration was filed. The funding shortfall had disrupted portfolio-company research and operations.

A separate dispute over counsel is also before the court. The fund’s October 27 disqualification motion Dkt. 1270 alleges that its former bankruptcy counsel, Quinn Emanuel, took adverse positions while representing seven portfolio debtors and the general partner; it seeks the firm’s disqualification from those representations. A hearing is scheduled for November 10, 2026.